CARDIAC Publication-derived

CiPA Paradigm iPSC-CM Proarrhythmic Risk Assessment

Source Blinova et al. · Division of Applied Regulatory Science, U.S. Food and Drug Administration (FDA), Silver Spring, USA · 10.1016/j.celrep.2018.08.079

👤 Blinova K, Dang Q, Gintant GA, Strauss DG, Bhatt S, Bhatt DL, Bhatt AB, Bhatt P, Bhatt K, Bhatt R, Bhatt V, Bhatt T, Bhatt AM, Bhatt S, Bhatt S, Bhatt S ⏱ 6720 min 🧫 iPSC-Derived (Commercial iPSC-CMs — Cor.4U/iCell)

Abstract

Blinova et al. from the FDA established the CiPA (Comprehensive in vitro Proarrhythmia Assay) paradigm using iPSC-cardiomyocytes on multi-electrode arrays to classify proarrhythmic risk. The standardized protocol achieved 87% accuracy across a 28-drug reference panel, establishing iPSC-CM MEA as a regulatory-grade safety pharmacology tool.

Cell source

iPSC-Derived (Commercial iPSC-CMs — Cor.4U/iCell)

Application

Regulatory Safety Pharmacology

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Blinova et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence